First Habib Modaraba (PSX:FHAM)

Revance Therapeutics Revenue

First Habib Modaraba had revenue of 328.21M PKR in the quarter ending March 31, 2025, a decrease of -1.15%. This brings the company's revenue in the last twelve months to 1.48B, up 15.86% year-over-year. In the fiscal year ending June 30, 2024, First Habib Modaraba had annual revenue of 1.37B with 64.93% growth.

• Revenue (ttm): 1.48B
• Revenue Growth: +15.86%
• P/S Ratio: 1.95
• Revenue / Employee: 17.23M
• Employees: 86
• Market Cap: 2.89B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2024	1.37B	540.34M	64.93%
Jun 30, 2023	832.14M	306.84M	58.41%
Jun 30, 2022	525.30M	62.82M	13.58%
Jun 30, 2021	462.48M	117.10M	33.90%
Jun 30, 2020	345.38M	-17.57M	-4.84%